Form 4: 4D Molecular Therapeutics' Chief Legal Officer Exercises and Sells Stock Options
SEC Form 4 Filing
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.
Summary
- On July 1, 2024, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, exercised stock options to acquire common stock.
- He exercised options for 1,332 shares at $6.49 and 2,916 shares at $8.04.
- Bizily then sold 4,248 shares of common stock at a weighted average price of $21.3648.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on October 10, 2023.
- Following these transactions, Bizily directly owns 1,737 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of insider trading. The sale could be for personal financial planning reasons and doesn't necessarily reflect a negative outlook on the company.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| October 10, 2023 | Date the Reporting Person adopted the 10b5-1 trading plan |
| June 16, 2022 | Vesting Commencement Date for 1,332 shares at $6.49 |
| September 1, 2022 | Vesting Commencement Date for 2,916 shares at $8.04 |
| July 1, 2024 | Date of stock option exercise and sale |
| June 17, 2032 | Expiration date for stock options at $6.49 |
| August 31, 2032 | Expiration date for stock options at $8.04 |
| July 03, 2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.